Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

BACKGROUND: Biliary tract cancer (BTC) has a high mortality. Primary diagnosis is frequently delayed due to mostly unspecific symptoms, resulting in a high number of advanced cases at the time of diagnosis. Advanced BTCs are in principle chemotherapy sensitive as determined by improved disease contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Perkhofer, L., Berger, A. W., Beutel, A. K., Gallmeier, E., Angermeier, S., Fischer von Weikersthal, L., Goetze, T. O., Muche, R., Seufferlein, T., Ettrich, T. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813114/
https://www.ncbi.nlm.nih.gov/pubmed/31646981
http://dx.doi.org/10.1186/s12885-019-6142-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813114/
https://www.ncbi.nlm.nih.gov/pubmed/31646981
http://dx.doi.org/10.1186/s12885-019-6142-y

Ejemplares similares